← Back to Search

Antiviral

Tenofovir Disoproxil Fumarate Safety for HIV

Phase 3

Waitlist Available

Research Sponsored by Gilead Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients who have completed another study on tenofovir DF without toxicity

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is looking at the safety of a drug for people who have HIV and have participated in other studies on the same drug.

Who is the study for?

This trial is for HIV-infected patients who have previously been part of other tenofovir DF studies without experiencing toxicity. Participants must be willing to use effective birth control during the study and for a month after. Those with kidney issues, on systemic steroids, or taking certain drugs that may harm the kidneys cannot join.Check my eligibility

What is being tested?

The study tests the safety of tenofovir disoproxil fumarate (tenofovir DF) when taken alongside other anti-HIV medications in patients who've tolerated different doses well in past trials and might benefit from continued treatment.See study design

What are the potential side effects?

Potential side effects include those commonly associated with antiretroviral therapy such as nausea, vomiting, diarrhea, dizziness, and potential kidney problems. Specific side effects related to tenofovir DF will be closely monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I completed a study on tenofovir DF without experiencing side effects.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Gilead SciencesLead Sponsor

1,082 Previous Clinical Trials

842,841 Total Patients Enrolled

Media Library

Tenofovir Disoproxil Fumarate (Antiviral) Clinical Trial Eligibility Overview. Trial Name: NCT00007436 — Phase 3

Human Immunodeficiency Virus Infection Research Study Groups:

Human Immunodeficiency Virus Infection Clinical Trial 2023: Tenofovir Disoproxil Fumarate Highlights & Side Effects. Trial Name: NCT00007436 — Phase 3

Tenofovir Disoproxil Fumarate (Antiviral) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00007436 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this drug been federally sanctioned for medical use?

"This is a Phase 3 trial, which means there is some data supporting efficacy and multiple rounds of data supporting safety. Therefore, the Power team rates this treatment's safety as a 3."

Answered by AI

Is this clinical test available to elderly patients?

"Children between the ages of 0 and 0 can qualify for this clinical trial, which is one of 109 similar trials for minors. For elderly patients, this trial is one of 364."

Answered by AI

Can you tell me how many hospitals are conducting this research?

"If you are considering enrolling in this clinical trial, know that there are 19 different sites currently recruiting patients. These locations include Providence, Denver and Houston. To reduce travel burdens, patients are encouraged to enroll at the site closest to them."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients

2024. "The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00007436.

All > Hiv Infection > Cte